RxDoctor Payments Data

Gregory Coffman, MD

Cardiovascular Disease · Lakeland, FLNPI 1669867552

Payments from drug & device makers

$3,852in general payments, 2019–2025

Across 186 payments — averaging $20.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$647
  • E.r. Squibb & Sons, L.L.C.$423
  • Boehringer Ingelheim$412
  • AstraZeneca$392
  • Merck$344
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$319
  • plus $1K from 14 others

What the payments were for

  • Food & beverage$3,56793%
  • Education$2857%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,852 in reported general payments places this provider in the 50th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$1,535,588
Medicare patients
2,651
Services billed
10,436

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban559$659,597
EntrestoSacubitril/Valsartan144$196,398
XareltoRivaroxaban117$126,811
JardianceEmpagliflozin102$124,286
Repatha SureclickEvolocumab29$45,559
FarxigaDapagliflozin Propanediol13$17,243
Dabigatran EtexilateDabigatran Etexilate Mesylate35$12,320
Praluent PenAlirocumab18$10,610
Metoprolol Succinate482$6,930
Amiodarone Hcl69$4,780
Atorvastatin Calcium364$4,092
Ranolazine ErRanolazine29$3,504
Diltiazem 24hr Er (Cd)Diltiazem Hcl104$3,365
Flecainide Acetate63$3,323
Losartan Potassium336$3,229

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$305$659,597559 claims
NovartisEntresto$647$196,398144 claims
Johnson & JohnsonXarelto$83$126,811117 claims
Boehringer IngelheimJardiance$412$124,286102 claims
AstraZenecaFarxiga$392$17,24313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Lakeland

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →